GRAL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Grail Inc (GRAL) is not a strong buy at this moment for a beginner investor with a long-term horizon. The stock has mixed signals, with no immediate positive catalysts, weak financial performance, and a lack of strong trading signals. It is better to monitor the stock for further developments, especially regarding its regulatory milestones and financial improvements.
The technical indicators are mixed. The MACD is positive but contracting, RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 49.698, with support at 45.416 and resistance at 53.98. This suggests a bearish trend in the short term.
The company is a leader in the multi-cancer early detection market with its Galleri test. Analysts believe it has a first-mover advantage and potential for growth in the long term, especially with FDA approval expected in 2027.
Insiders are selling heavily, with a 191.52% increase in selling activity over the last month. The NHS-Galleri study missed its primary endpoint, raising concerns about the product's competitive advantage. Regulatory and reimbursement uncertainties persist, and hedge funds remain neutral.
In Q4 2025, revenue increased by 13.97% YoY, but the company remains unprofitable with a net loss of -$99.18M. EPS dropped by -15.92% YoY, and gross margin declined significantly to -25.54%, indicating operational inefficiencies.
Analysts are mixed on the stock. Recent ratings include Neutral from Mizuho and Piper Sandler with price targets of $58 and $54, respectively. Guggenheim and TD Cowen have Buy ratings with lower price targets of $75 and $65, citing the recent selloff as an attractive entry point. However, concerns about missed study endpoints and regulatory risks weigh on sentiment.
